Nxera pharma notes neurocrine biosciences presents new positive data from phase 2 study of nbi-1117568 in adults with schizophrenia at american society of clinical psychopharmacology 2025

Tokyo, japan and cambridge, uk, 29 may 202 5 – nxera pharma co., ltd. (“nxera” or “the company”; tse 4565) notes that neurocrine biosciences, inc. announced that it had presented new positive data from the phase 2 study of nbi-1117568 in adults with schizophrenia at the american society of clinical psychopharmacology (ascp) 2025 annual meeting in scottsdale, arizona.
NBIX Ratings Summary
NBIX Quant Ranking